Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $133.99 USD
Change Today +0.59 / 0.44%
Volume 384.0K
TFX On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

teleflex inc (TFX) Key Developments

Teleflex Incorporated Receives FDA Market Clearance for its ARROW Endurance™ Extended Dwell Peripheral Catheter System

Teleflex Incorporated announced that its ARROW Endurance™ Extended Dwell Peripheral Catheter System received market clearance from the U.S. Food and Drug Administration (FDA). The new device is a peripheral catheter systm in which the catheter is cleared by the FDA to dwell up to 29 days. The extended dwell catheter enables hospitals to avoid using multiple PIVs to achieve longer dwell times while also avoiding the extra clinical risks and expenses associated with a peripherally inserted central catheter (PICC). The intravascular catheter is intended for short-term use (up to 29 days) to permit delivery of infusion therapies, pressure monitoring, high pressure injection (325 psi max.), and withdrawal of blood. Designed to maximize performance and ease-of-use, the extended dwell system is engineered to increase safety for clinicians and reduce needle sticks for patients. The device contains a passive needle safety that reduces the risk of accidental needle stick injuries and exposure to blood. The closed system design makes it less likely that clinicians will accidentally come in contact with bloodborne pathogens. Teleflex expects to launch the ARROW Endurance™ Extended Dwell Peripheral Catheter System in the United States later in 2015.

Teleflex Incorporated Announces Worldwide Voluntary Recall of Hudson RCI® LIFESAVER® Neonate Manual Resuscitator

Teleflex Incorporated announced that the U.S. Food and Drug Administration (FDA) has classified the voluntary medical device recall of Hudson RCI® LIFESAVER® Neonate Manual Resuscitator as a Class 1 recall. FDA defines Class I recalls as, “a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death". Teleflex is recalling the products referenced above because the intake port may be blocked, which can cause the bag to fail to fill. No patient injury or harm has been reported, however, a delay in treatment may occur while another resuscitator is obtained. A delay in treatment may potentially lead to adverse consequences such as hypoxia. Teleflex notified both domestic and foreign hospitals and distributors via an Urgent Medical Device recall letter dated May 14, 2015. This recall involves the retrieval of unused product in the field.

Teleflex Wins Multiple Awardees Contract Award from NHS London Procurement Partnership for Total Cardiology Solutions

Teleflex has won a zero pound multiple awardees contract award from NHS London Procurement Partnership for total cardiology solutions (Interventional Radiology Products used in Cardiology). No contract amount was specified (GBP 0).

Teleflex Incorporated Redeems $250,000,000 Outstanding Principal Amount of its 6.875% Senior Subordinated Notes Due 2019

On June 1, 2015 Teleflex Incorporated redeemed $250,000,000 outstanding principal amount of its 6.875% Senior Subordinated Notes due 2019 using borrowings under the Company's revolving credit agreement and securitization facility and cash on hand. The Redeemed Notes were redeemed at a redemption price equal to 103.438% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the Redemption Date.

Teleflex Incorporated Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 02:00 PM

Teleflex Incorporated Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 02:00 PM. Venue: Four Seasons Hotel, Chicago, Illinois, United States. Speakers: Thomas E. Powell, Chief Financial Officer and Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TFX:US $133.99 USD +0.59

TFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
IDEXX Laboratories Inc $72.73 USD +1.39
PerkinElmer Inc $52.92 USD +1.50
Sirona Dental Systems Inc $103.78 USD +1.01
STERIS Corp $69.13 USD +0.44
West Pharmaceutical Services Inc $59.87 USD +0.09
View Industry Companies
 

Industry Analysis

TFX

Industry Average

Valuation TFX Industry Range
Price/Earnings 33.2x
Price/Sales 3.1x
Price/Book 2.9x
Price/Cash Flow 29.6x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TELEFLEX INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.